Group One Trading’s Phio Pharmaceuticals PHIO Stock Holding History

Group One Trading’s Portfolio PHIO Stock Details PHIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5	Closed	-$186	–	7771
2022 Q4	$186	Sell	5 -460	-99%	-$23.6K	﹤0.01%	7040
2022 Q3	$29K	Sell	465 -11	-2%	-$833	﹤0.01%	5832
2022 Q2	$37K	Buy	+476	New	+$44.7K	﹤0.01%	5816

Other funds holding PHIO

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading's PHIO Position: Q2 2022 in Review

Group One Trading sold out of Phio Pharmaceuticals (PHIO) in Q2 2022, closing a stake of 3 shares — an estimated $282 sold.

Group One Trading first reported a position in PHIO in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 12 funds tracked by Wall St. Rank hold PHIO as of Q2 2022.

Group One Trading reported no remaining Phio Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Group One Trading sold 3 Phio Pharmaceuticals shares in Q2 2022, an estimated $282.
Group One Trading first reported a position in Phio Pharmaceuticals in Q4 2021 and held it in 2 quarters.
Group One Trading's Phio Pharmaceuticals position peaked at $1K in Q4 2021.
12 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q2 2022.

Based on Group One Trading's 13F filing for Q2 2022, filed 11 Aug 2022.